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SHORT COMMNUNICATION
Phase I study of 21 days continuous infusion with vindesine
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Vindesine (VDS) is a semi-synthetic vinca alkaloid.
Continuous infusion schedules have resulted in an improved
therapeutic index for this, as well as for related alkaloids
(Yap et al., 1981; Lokich et al., 1984; Bodey et al., 1980b;
Jackson et al., 1984a). Continuous administration of the
drug over a few days allowed augmentation of the dosage of
VDS without increasing toxicity. Responses were seen with
continuous infusion in tumours resistant to bolus injections
of vinca alkaloids (Mathe et al., 1978; Mascret et al., 1983).
The rationale for such schedules has been based on the
relatively short plasma half-life of VDS in pharmacological
studies (Jackson et al., 1984b), and the fact that vinca
alkaloids are cell cycle specific drugs. We performed a study
of a 21-day continuous infusion of VDS administered with
an ambulatory pump.
Eligibility criteria for the study were: age 21-75 years, no
prior treatment with vinca alkaloids, normal blood count,
bilirubin <35mmoll-1, creatinine <130umoll -1, absence
of neurological disorder and Karnofsky score >60. For
continuous infusion an implantable venous access port
(Greidanus et al., 1987) (Infuse A Port) and a portable pump
(Graseby Medical MS 16Atm syringe driver) were used. A
20mlluer lock syringe with VDS dissolved in 0.9% NaCl was
connected to the port via an extension tube and a Huber
point needle (Greidanus et al., 1987). Patients formulated the
VDS at home and replaced syringes every other day in order
to assure drug stability. Treatment was performed on an
outpatient basis as described before (De Vries et al., 1987).
A starting dose of 0.2mgm 2day- for 21 days VDS was
chosen, followed by a 3 weeks rest period. Toxicity was
evaluated according to WHO on days 7, 14, 21, 37 and
42 after start of therapy. Unacceptable toxicity and therefore
abolition of treatment was defined as neurotoxicity grade 2
and/or any other parameter reaching grade 3 toxicity
according to the WHO grading system (WHO, 1978). For
pharmacokinetic analysis blood samples were drawn at 19h,
40h, 8, 13 and 14 days after start and 24h after cessation of
therapy. The concentration of VDS in plasma was
determined with HPLC and electrochemical detection
according to Vendrig et al. (1988).
In four patients (see Table I for patient characteristics)
therapy with VDS, dose 0.2mgm-2day-1, was started.
Haematological toxicity was limited, only one patient
developed leukopaenia grade 1. Liver function disturbances
due to VDS were not seen. Neurotoxicity was the major
complication and led to drug withdrawal in three patients
during the first course, whereas the fourth patient did not
have any sign of neurotoxicity. In the second week of
treatment these three patients started to complain about pain
in the legs and knees and progressive muscle weakness. They
had problems climbing staircases or walking more than a
few metres, despite cessation of treatment. Eventually one
patient was so severely disabled that she had to use a wheel-
chair. After cessation of therapy muscle strength was
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regained in all patients over a period of 3-4 weeks. Two of
these three patients had in addition severe one-sided jaw
pain and one low back pain, and the feeling of being
battered. Jaw pain started also in the second week; the patient
needed analgesics and the pain subsided after
discontinuation of treatment. None complained about
paresthesias in the upper or lower extremities or had these
on physical examination. Signs of autonomic neuropathy
were not seen.
There were no complications of the drug delivery system
or the venous catheter. Preparation of the VDS solution at
home by the patients themselves proved to be feasible
without any problems. Plasma concentrations of VDS were
determined in patient number 1 (Table I). After 19 and 40h
and 8 days infusion the concentrations of the samples were
0.5, 0.6 and 0.8ng VDSml-1, respectively. The
concentration of VDS in samples taken during infusion (days
13 and 14) and after the cessation of therapy were below the
determination limit (0.5ngml-1 plasma).
In various studies with VDS (Yap et al., 1981; Mathe et
al., 1978; Mascret et al., 1983; Bodey et al., 1980a; Carlson
& Sikic, 1983) it is shown that 5 day continuous infusion
makes it possible to administer a higher drug dose with
similar or less toxicity compared to bolus injection. Dose
limiting side effects were haematological and neurological
toxicity. Been et al. (1980) found more profound
neurotoxicity with repeated courses. Gralla et al. (1981)
found, in a weekly VDS schedule, that the degree of
neuropathy was related to the total dose of VDS received. In
one of these studies muscle pain, arthralgias, jaw pain and
the feeling of being battered were described as side effects.
In a study with prolonged infusion of vinblastine (median
duration 30 days, maximum 81 days) no neurological
toxicity was seen (Lokich et al., 1984). The dose limiting side
effect was leukopaenia and the maximum tolerated dose was
0.75mgm-2day-1 vinblastine for 30 days. In our study, the
intended 0.2mgm-2day-I for 21 days could not be
administered in three out of four patients due to
neurotoxicity. The total dose administered in these patients
(mean 5.6mg), if administered as a bolus injection, does not
usually lead to neurotoxicity. Pharmacokinetic analysis
performed in one patient showed no plasma accumulation of
VDS during the 14 day treatment period. This does not
exclude accumulation of the drug in nerve or muscle tissue.
In a pharmacokinetic analysis of a 5 day infusion regimen
(Jackson et al., 1984b) there was also no accumulation of the
drug found. The area under the curve (AUC) calculated for
a patient with a hypothetical steady state plasma level of
0.8ngml- (the highest level detected in one of our patients)
is still smaller than the AUC in the 2 day infusion (total
dose 5.4mg) or bolus injection (total dose 4.0-5.0mg) found
by others (Jackson et al., 1984b; Rahmani et al., 1985). In
the study of Jackson et al. (1984b) only mild neurotoxicity
was seen.
It can be concluded that VDS cannot be administered
safely for 21 days at the low dose of 0.2mgm-2day-1.
Therefore VDS infusion for longer periods does not seem to
result in a more favourable dose:toxicity ratio. Due to severe
neurotoxicity this regimen is not recommended for further
studies.
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Table I Patient characteristics
Total cumulative
dose
Number Sex Age Diagnosis Days of treatment administered (mg)
I F 68 Renal cell carcinoma 14 4.3
2 F 61 Renal cell carcinoma 16 5.6
3 M 56 Gastric carcinoma 21 9.45
4 F 42 Malignant melanoma 19 7.0
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